Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Xenon Pharmaceuticals excels in epilepsy treatment with strong IP strategy

Xenon Pharmaceuticals demonstrated strong performance and promising efficacy data for XEN1101 in epilepsy treatment, supported by a robust IP strategy and CNS penetration.
While facing challenges in patient enrollment and rising expenses, the company is exploring new therapeutic areas and potential milestone payments through partnerships.
Opportunities lie in expanding XEN1101's market reach, establishing a leadership position in epilepsy treatment, and navigating uncertainties in pediatric indications and generic competition.

Xenon Pharmaceuticals advances epilepsy program amid financial stability and challenges

Xenon Pharmaceuticals showcased progress in their epilepsy program and financial stability, while addressing challenges in enrollment dynamics and competitive pressures.
The company's focus on managing R&D expenses and upcoming milestones reflects a strategic approach to advancing their clinical programs.
Opportunities in the epilepsy market and ongoing formulation development for pediatric patients position Xenon for potential growth and innovation.

Xenon Pharmaceuticals excels in trials and finances, eyes global expansion

Xenon Pharmaceuticals showcases strong performance in key trials and financial stability, supported by positive market reception and strategic leadership additions.
While facing challenges in trial completion and enrollment trends, the company has opportunities to expand market reach, innovate in treatment approaches, and explore global partnerships.
Overall, Xenon's focus on advancing novel therapies for neurological disorders positions it well for future growth and success in the competitive pharmaceutical landscape.

Xenon Pharmaceuticals advances epilepsy and MDD treatments, poised for growth

Xenon Pharmaceuticals showcased strong performance in advancing XEN1101 for epilepsy and MDD treatments, backed by extensive data and strategic partnerships.
While facing challenges in enrollment timelines and technical complexities, the company is well-positioned financially and strategically for future growth.
Opportunities abound in addressing unmet needs, expanding drug applications, and advancing new molecules into clinical development.
Overall, Xenon Pharmaceuticals' Q3 earnings call highlighted a promising outlook for drug development and market positioning.

Xenon Pharmaceuticals excels in Q4, poised for growth in epilepsy and MDD

Xenon Pharmaceuticals showcased strong financials, program advancements, and market insights in Q4 2023, positioning the company well for future growth.
The company's focus on safety, tolerability, and efficacy in MDD treatment, along with leveraging learnings across programs, demonstrates strategic foresight.
While facing challenges in R&D spend allocation and regulatory discussions, Xenon can capitalize on opportunities for operational efficiency and market expansion.
Investor interest in Xenon's pipeline and the potential of its programs in epilepsy and MDD highlight a promising trajectory for the company.

Xenon Pharmaceuticals reports strong Q1 performance and addresses market needs

Xenon Pharmaceuticals is well-positioned with a strong financial base and promising pipeline.
The company faces challenges in conducting well-powered MDD trials and addressing market needs.
Opportunities lie in the substantial unmet need in the major depressive market and azetukalner's potential benefits.
Strategic planning and FDA alignment support Xenon's progress in key therapeutic areas.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 – a differentiated Kv7 potassium channel modulator – administered as adjunctive treatment in adult patients with focal epilepsy.

Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy

BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial on Monday, October 4, 2021 at 7:30 am Eastern Time.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE' Clinical Trial of XEN1101

Investors need to pay close attention to Xenon (XENE) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Xenon (XENE) Stock?

Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021 Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021

Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone

BURNABY, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Kenney, M.D. as Chief Medical Officer, effective immediately. Dr. Kenney will oversee all clinical development and medical affairs strategies, guiding the development of Xenon's portfolio of neurology-focused therapeutic programs.

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer

Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q2 2021 Results - Earnings Call Transcript

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -4.08% and -13.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Lags Revenue Estimates

Topline Data from XEN1101 Phase 2b “X-TOLE” Clinical Trial Anticipated Late September to Mid-October 2021

Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

BURNABY, British Columbia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings as well as a virtual panel discussion at the 12th Annual Wedbush PacGrow Healthcare Conference.

Xenon Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

BURNABY, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, August 11, 2021.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

BURNABY, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in a virtual fireside chat at the William Blair Biotech Focus Conference 2021.

Xenon Pharmaceuticals to Participate at the William Blair Biotech Focus Conference 2021

Webinar to be broadcast live on Monday, July 12, 2021 beginning at 10 am ET Webinar to be broadcast live on Monday, July 12, 2021 beginning at 10 am ET

Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders

BURNABY, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders (the “Annual Meeting”) held today on June 3, 2021.

Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders

BURNABY, British Columbia, May 31, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will participate in the following investor conference:

Xenon Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q1 2021 Results - Earnings Call Transcript

Topline Data from XEN1101 Phase 2b “X-TOLE” Clinical Trial Anticipated by End of Third Quarter of 2021

Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

BURNABY, British Columbia, March 29, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the Company will participate in a fireside chat at the following virtual investor conference:

Xenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS Day

BURNABY, British Columbia, March 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 5,135,135 common shares, which includes 810,810 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase 1,081,081 common shares. The common shares were offered at a public offering price of $18.50 per common share and the pre-funded warrants were offered at a price of $18.4999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $115.0 million.

Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

BURNABY, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 4,324,325 common shares and, in lieu of common shares to a certain investor, pre-funded warrants to purchase up to 1,081,081 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $18.50 per common share and the pre-funded warrants are being offered at a price of $18.4999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $100.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 810,810 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about March 12, 2021, subject to customary closing conditions.

Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering

BURNABY, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) --  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to purchase up to an additional 15% of the common shares offered in the offering, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

U.S. FDA IND acceptance and IRB approval in place for investigator-sponsored trial, expected to be initiated in the second quarter of 2021 U.S. FDA IND acceptance and IRB approval in place for investigator-sponsored trial, expected to be initiated in the second quarter of 2021

Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)

Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q4 2020 Results - Earnings Call Transcript

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 15.00% and 47.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Tops Revenue Estimates

Shares of Xenon Pharmaceuticals (NASDAQ:XENE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 17.07% over the past year to ($0.34), which beat the estimate of ($0.40).

Recap: Xenon Pharmaceuticals Q4 Earnings

XEN1101 Phase 2b “X-TOLE” Clinical Trial in Adult Focal Epilepsy on Track for Topline Data in  Third Quarter of 2021

News for Xenon Pharmaceuticals Stock (XENE)